Effects of Cyclosporine A on Pancreatic Insulin Secretion

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Our primary aim is to investigate if cyclosporine A reduces insulin secretion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oslo School of Pharmacy
• Treatments: Cyclosporine; Cyclosporins; Insulin

Criteria

Inclusion Criteria:

• Renal failure patients on dialysis which is planned to receive a renal transplant

Exclusion Criteria:

• Age below 18 years or above 75 years

• Pregnancy

• Breast feeding mothers

• Diabetes mellitus /WHO criteria)

• Dialysis treatment less than 2 months

• Serious coronary heart disease

• Unstable angina pectoris

• Recent acute infarction (less than 3 months)

• Non-compensated heart failure

• Simultaneous treatment with glucocorticosteroids (e.g. prednisolone, dexamethasone), diltiazem, verapamil, erythromycin, clarithromycin, telithromycin, rifampicin, fluconazole, itraconazole, ketoconazole, voriconazole, indinavir, nelfinavir, ritonavir, nefazodone, bosentan, carbamazepine, St. John's worth, grapefruit.